RU2018130831A - Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии - Google Patents

Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии Download PDF

Info

Publication number
RU2018130831A
RU2018130831A RU2018130831A RU2018130831A RU2018130831A RU 2018130831 A RU2018130831 A RU 2018130831A RU 2018130831 A RU2018130831 A RU 2018130831A RU 2018130831 A RU2018130831 A RU 2018130831A RU 2018130831 A RU2018130831 A RU 2018130831A
Authority
RU
Russia
Prior art keywords
composition
inhibitor
entinostat
class
administered
Prior art date
Application number
RU2018130831A
Other languages
English (en)
Russian (ru)
Other versions
RU2018130831A3 (https=
Inventor
Роберто Пили
Original Assignee
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн filed Critical Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
Publication of RU2018130831A publication Critical patent/RU2018130831A/ru
Publication of RU2018130831A3 publication Critical patent/RU2018130831A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2018130831A 2016-01-28 2017-01-27 Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии RU2018130831A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662288121P 2016-01-28 2016-01-28
US62/288,121 2016-01-28
PCT/US2017/015389 WO2017132536A1 (en) 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies

Publications (2)

Publication Number Publication Date
RU2018130831A true RU2018130831A (ru) 2020-03-02
RU2018130831A3 RU2018130831A3 (https=) 2020-04-23

Family

ID=58010402

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018130831A RU2018130831A (ru) 2016-01-28 2017-01-27 Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии

Country Status (13)

Country Link
US (1) US10813919B2 (https=)
EP (1) EP3407913A1 (https=)
JP (1) JP2019503386A (https=)
KR (1) KR20180104122A (https=)
CN (1) CN108883179A (https=)
AU (1) AU2017211383A1 (https=)
BR (1) BR112018015291A2 (https=)
CA (1) CA3013047A1 (https=)
IL (1) IL260765A (https=)
MX (1) MX2018009247A (https=)
RU (1) RU2018130831A (https=)
WO (1) WO2017132536A1 (https=)
ZA (1) ZA201805066B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
IL264068B2 (en) * 2018-01-05 2023-07-01 Great Novel Therapeutics Biotech & Medicals Corp Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells
CN111836636A (zh) * 2018-01-12 2020-10-27 维拉克塔治疗公司 用于细胞免疫疗法的表观遗传修饰剂
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
CN112569360A (zh) * 2019-09-30 2021-03-30 中国医学科学院药物研究所 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
EP4705341A1 (en) * 2023-05-05 2026-03-11 Euro-Celtique S.A. Combinations for treating cancer
WO2024238811A2 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same
US12553903B2 (en) 2023-06-01 2026-02-17 Cg Pharmaceuticals, Inc Ivaltinostat combination therapy for treating pancreatic cancer
WO2025155922A1 (en) * 2024-01-19 2025-07-24 The Trustees Of Indiana University Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
US9987258B2 (en) 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
ES2986548T3 (es) * 2015-03-20 2024-11-11 Syndax Pharmaceuticals Inc Combinación de inhibidor de HDAC y anticuerpo anti-PD-1 para el tratamiento del cáncer, en donde la combinación no comprende 5-azacitidina
US20180250320A1 (en) 2015-08-26 2018-09-06 The Johns Hopkins University Compositions and methods for treating solid tumors
BR112018003238A2 (en) * 2015-09-02 2018-09-25 Syndax Pharmaceuticals, Inc. patient selection for combination therapy

Also Published As

Publication number Publication date
MX2018009247A (es) 2019-03-11
IL260765A (en) 2018-10-31
US20190030011A1 (en) 2019-01-31
WO2017132536A1 (en) 2017-08-03
US10813919B2 (en) 2020-10-27
JP2019503386A (ja) 2019-02-07
CA3013047A1 (en) 2017-08-03
EP3407913A1 (en) 2018-12-05
AU2017211383A1 (en) 2018-08-16
RU2018130831A3 (https=) 2020-04-23
BR112018015291A2 (pt) 2018-12-18
KR20180104122A (ko) 2018-09-19
ZA201805066B (en) 2019-05-29
CN108883179A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
RU2018130831A (ru) Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии
JP2019503386A5 (https=)
US20240342172A1 (en) Methods and compositions for treating viral or virally-induced conditions
RU2012135396A (ru) Способы лечения рака с применением ингибитора аутофагии на основе тиоксантона
SA522433000B1 (ar) مركبات فلورو ألكيل-أوكساديازول واستخداماتها
Demonté et al. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies
JP2021038228A5 (https=)
ES2342378T3 (es) Inhibidor de degradacion de matriz extracelular del cartilago artrodial.
US20170027971A1 (en) Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
AU751701B2 (en) Ace inhibitor-MMP inhibitor combinations
JP2009539862A5 (https=)
EA200801492A1 (ru) Фармацевтическое применение замещенных амидов
RU2018106914A (ru) 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция
EP1592665A4 (en) NEW BENZAMID DERIVATIVES AS HISTONDEACETYLASEINHIBITORS WITH EFFECTIVE DIFFERENTIATION AND ANTIPROLIFERATION EFFECT
EA200500583A1 (ru) Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение
HRP20100577T1 (hr) Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP2009521424A (ja) 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤
RU2016135952A (ru) Композиции ингибитора дофа-декарбоксилазы
RU2016136193A (ru) Аминокарбонилкарбаматные соединения
RU2011140701A (ru) Замещенные 3-амино-2-меркаптохинолины в качестве kcnq2/3 модуляторов
EA202190621A1 (ru) Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты
RU2008107871A (ru) Применение ингибиторов hdac для лечения миеломы
WO2022169755A8 (en) Sulfonamide substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereof
WO2007049262A1 (en) Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20211015